Form 4: BrainStorm Cell Therapeutics Director Option Grant
Director Equity Compensation Disclosure
Director Anthony J. Polverino was granted 150,000 stock options in BrainStorm Cell Therapeutics Inc. (BCLI).
Summary
- Director Anthony J. Polverino received a grant of 150,000 stock options.
- The options have an exercise price of $0.70 per share.
- The grant was issued under the Issuer's 2014 Stock Incentive Plan.
- Vesting occurs in two tranches: 50% on the grant date and 50% on the six-month anniversary.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding director compensation with no immediate impact on company operations or financial health.
Positives
- Aligns director interests with long-term shareholder value through equity-based compensation.
Negatives
- Results in potential future dilution of existing shareholders upon exercise of the options.
Risks
- The value of the options is dependent on the future market performance of BCLI common stock.
- Vesting is contingent upon the director remaining with the company.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of equity compensation for a director.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to incentivize leadership and preserve cash reserves, though they are closely monitored by investors for potential dilution impact.
Comparison to Industry Standards
- The use of a 2014 Stock Incentive Plan is consistent with standard corporate governance practices for small-cap biotech firms.
- The vesting schedule (50% immediate, 50% six-month) is relatively aggressive compared to standard multi-year cliff or graded vesting schedules.
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of the remaining 50% of options on August 26, 2026.
Key Dates
| Date | Description |
|---|---|
| 02/26/2026 | Date of grant and earliest transaction date. |
| 08/26/2026 | Six-month anniversary and final vesting date for the options. |
| 02/26/2036 | Expiration date of the stock options. |
| 05/20/2026 | Date of signature on the filing. |
Keywords
BCLI, BrainStorm Cell Therapeutics, Stock Options, Director Compensation, Insider Transaction, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.